The effect of valsartan and captopril on lipid parameters in patients with type II diabetes mellitus and nephropathy

International Journal of Clinical Practice

Volumn 53, Issue 8, 1999, Pages

  Cheung, Raphael ^e   Lewanczuk, R Z ^e   Rodger, N W ^a   Huff, M W ^b   Oddou Stock, P ^c   Botteri, F ^c   Pecher, E ^c   Muirhead, N ^d  

^a St Josephs Hospital   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c NOVARTIS PHARMA AG   (Switzerland)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CAPTOPRIL; CHOLESTEROL; LIPID; TRIACYLGLYCEROL; VALSARTAN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINUSITIS; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VIRUS INFECTION;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LIPIDS; MALE; MIDDLE AGED; TETRAZOLES; VALINE;

EID: 0343339891     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Pyorala K, Laakso M, Uusiupa M. Diabetes and atherosclerosis: an epidemiological view. Diabetes Metab Rev 1487; 3: 463-524.
2. Robertson WB, Strong JP. Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Invest 1968; 18: 538-551.
3. Laakso M, Voutilainen E, Sarlund H et al. Serum lipids and lipoproteins in middle aged non-insulin dependent diabetics. Atherosclerosis 1985; 56: 271-281.
4. Masarei JRL, Kiivery HT, Stanton K, Davies RE. Cholesterol and lipoprotein-cholesterol levels in Western Australian rural diabetics. Aust NZ J Med 1982; 12: 241-247.
5. Masarei JRL, Kiivery HT, Stanton K. Risk factors for cardiovascular disease in a diabetic population. Pathology 1986; 18: 89-93.
6. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Brenner BM, Laragh JH, Eds. Hypertension. New York: Raven Press, 1990: 1287-1319.
7. Waeher B, Nussberger J, Brunner HR. Angiotensin-converting enzyme inhibitors in hypertension. In: Laragh JH, Brenner BM, Eds. Hypertension: pathophysiology, diagnosis unit management, 2nd edn. New York: Raven Press, 1995: 2861-2872.
8. Verme-Gibboney C. Oral angiotensin converting enzyme inhibitors. Am J Health Syst Pharm 1997; 54: 2689-2703.
9. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. New Engl J Med 1993; 329: 1456-1462.
10. Viherti G, Mogensen CE, Groop LC. Pauls JF. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. JAMA 1994; 271: 275-279.
11. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.
12. Ferner RE, Simpson JM, Rawlins MD. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. BMJ 1987; 294: 1119-1120.
13. Morice AH, Brown MJ, Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1989; 13: S59-SA2.
14. Semple PF, Herd GW. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. New Engl J Med 1986; 314: 61.
15. Rang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127: 1388-1401.
16. Weber MA. Angiotensin II receptor antagonists in the treatment of hypertension. Cardiol in Review 1997; 5: 72-80.
17. Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992; 90: 766-771.
18. Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993; 267: 657-663.
19. Gansevoort RT, de Zeeuw D, de Jong PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Intern 1994; 45: 861-867.
20. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403-1407.
21. Markham A, Goa KL. Valsartan: a review of its pharmacology and therapeutic use in essential hypertension. Drugs 1997; 54: 299-311.
22. Criscione L. Bradley WA, Bühlmayer P et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 1995; 13: 230-250.
23. Müller P, Cohen T, de Gasparo M et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47: 231-245.
24. Corea L, Cardoni O, Fogari R et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60: 341-346.
25. Holwerda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-1151.
26. Hegner G, Faust G, Freytag F et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide. Eur J Clin Pharmacol 1997; 52: 173-177.
27. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128: 1177-1183.
28. Weidmann P, de Courbon M, Ferrari P, Bohlen L. Serum lipoproteins during treatment with antihypertensive drugs. J Cardiovasc Phamacol 1993; 22: S98-S105.
29. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids, Ann Intern Med 1995; 122: 133-141.
30. Middeke M, Richter WO, Schwandt P, Holzgreve H. The effects of anti-hypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs hydrochlorothiazide plus captopril. Int J Clin Pharmacol Ther 1997; 35: 231-234.
31. Ames RP. A comparison of blood lipid and blood pressure responses during the treatment of systemic hypertension with indapamide and with thiazides. Am J Cardiol 1996; 77: 12b-16b.
32. Schmitz G, Stumpe KO, Herrmann W, Weidinger G. Effects of bunazosin and atenolol on serum lipids and apolipoproteins in a randomised trial. Blood Press 1996; 5: 354-359.
33. Schoenberger JA, Testa M, Ross AD et al. Efficacy, safety and quality of life assessment of captopril anlihypertensive therapy in clinical practice. Arch Intern Med 1990; 150: 301-306.
34. Jenkins AC, Dreslinski GR, Tadros SS et al. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol 1985; 7(suppl): S96-S101.
35. Martell N, Gill B, Marin R, et al. Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension. J Hum Hypertens 1998; 12: 69-72.
36. Bental T, Lishner M, Lalkin A et al. Comparison of enalapril to captopril by 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1997; 37: 514-519.
37. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. New Engl J Med 1993; 329: 1456-1462.
38. Huff MW, Telford DE, Woodcroft K, Strong WL. Mevinolin and cholestyramine inhibit the direct synthesis of low density lipoprotein apolipoprotein B in miniature pigs. J Lipid Res 1985; 26: 1175-1186.
39. 2+ precipitation procedure for quantitation of high density lipoprotein cholesterol. Clin Chem 1982; 28: 1378-1388.
40. Assmann G, Schult EH. Triglycerides and atherosclerosis: results from the prospective cardiovascular Munster Study. Atheroscler Rev 1991; 22: 1465-1477.
41. Manninen V, Tenkanen L, Koskinen P et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992; 85: 37-45.
42. Castelli WP. Epidemiology of triglycerides: a view from Framingham. Am J Cardiol 1992; 70: 3H-9H.
43. Lind L, Pollare T, Beme C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128: 1177-1183.